APA (7th ed.) Citation

P, V., S, T., F, L. T., P, C., S, H., H, K., . . . P, G. (2024). Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): A multicentre, randomised, controlled phase 2 trial. The Lancet. Oncology, 25(9), 1176. https://doi.org/10.1016/S1470-2045(24)00320-6

Chicago Style (17th ed.) Citation

P, Vera, et al. "Adaptive Radiotherapy (up to 74 Gy) or Standard Radiotherapy (66 Gy) for Patients with Stage III Non-small-cell Lung Cancer, According to [18F]FDG-PET Tumour Residual Uptake at 42 Gy (RTEP7-IFCT-1402): A Multicentre, Randomised, Controlled Phase 2 Trial." The Lancet. Oncology 25, no. 9 (2024): 1176. https://doi.org/10.1016/S1470-2045(24)00320-6.

MLA (9th ed.) Citation

P, Vera, et al. "Adaptive Radiotherapy (up to 74 Gy) or Standard Radiotherapy (66 Gy) for Patients with Stage III Non-small-cell Lung Cancer, According to [18F]FDG-PET Tumour Residual Uptake at 42 Gy (RTEP7-IFCT-1402): A Multicentre, Randomised, Controlled Phase 2 Trial." The Lancet. Oncology, vol. 25, no. 9, 2024, p. 1176, https://doi.org/10.1016/S1470-2045(24)00320-6.